Loading
NYSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$12.48
+$0.28 · +2.30%
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
Latest quote
$12.48
+$0.28 · +2.30%
After-hours
$12.48
$0.00 · 0.00%
Oct 9, 5:34 PM ET
Regular session · ET · Market data may be delayed.
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
Day range
Current $12.48
52-week range
Current $12.48
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
77
Undervalued
Sentiment
56
Mixed
Risk
31
Moderate Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
Day range
Current $12.48
52-week range
Current $12.48
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (INR) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 353.47B INR | 325.54B INR | 279.16B INR | 245.88B INR | 214.39B INR |
| Cost of goods sold | 166.95B INR | 135.11B INR | 115.56B INR | 106.54B INR | 100.55B INR |
| Gross profit | 186.52B INR | 190.43B INR | 163.61B INR | 139.34B INR | 113.84B INR |
| Research and development | 25.31B INR | 27.38B INR | 22.87B INR | 19.38B INR | 17.48B INR |
| Selling, general, and administrative | 112.34B INR | 93.87B INR | 77.2B INR | 68.03B INR | 62.08B INR |
| Operating expenses | 137.65B INR | 118.59B INR | 95.88B INR | 82.2B INR | 84.36B INR |
| Interest income | 8.28B INR | 2.68B INR | 2.28B INR | 1.18B INR | 965M INR |
| Interest expense | 3.93B INR | 2.83B INR | 1.71B INR | 1.43B INR | 958M INR |
| Depreciation and amortization | 21.68B INR | 17.06B INR | 14.84B INR | 12.64B INR | 11.82B INR |
| Operating income | 48.87B INR | 71.84B INR | 67.73B INR | 57.14B INR | 29.48B INR |
| Net income | 45.09B INR | 56.54B INR | 55.68B INR | 45.07B INR | 23.57B INR |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Cash distributions grouped by calendar year; partial years are marked.
$0.0915
2025 complete year+35.9% since 2021
2026 partial: $0.0834
$0.0673
2,021
$0.1531
2,022
$0.1941
2,023
$0.0808
2,024
$0.0915
2,025
$0.0834
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 24, 2026 | $0.0834Annual | Jul 9, 2026 | Aug 5, 2026 |
Dividend | Jul 25, 2025 | $0.0915Annual | Jul 10, 2025 | Aug 6, 2025 |
Dividend | Jul 30, 2024 | $0.4762Annual | Jul 15, 2024 | Aug 12, 2024 |
Dividend | Jul 28, 2023 | $0.4826Monthly | Jul 10, 2023 | Aug 11, 2023 |
Dividend | Jul 7, 2023 | $0.488Annual | Jul 10, 2023 | Aug 11, 2023 |
Dividend | Aug 1, 2022 | $0.3784Monthly | Jul 11, 2022 | Aug 12, 2022 |
Ex-dividend Jul 24, 2026
$0.0834
Annual
Record Jul 9, 2026 · Payment Aug 5, 2026
Ex-dividend Jul 25, 2025
$0.0915
Annual
Record Jul 10, 2025 · Payment Aug 6, 2025
Ex-dividend Jul 30, 2024
$0.4762
Annual
Record Jul 15, 2024 · Payment Aug 12, 2024
Ex-dividend Jul 28, 2023
$0.4826
Monthly
Record Jul 10, 2023 · Payment Aug 11, 2023
Ex-dividend Jul 7, 2023
$0.488
Annual
Record Jul 10, 2023 · Payment Aug 11, 2023
Ex-dividend Aug 1, 2022
$0.3784
Monthly
Record Jul 11, 2022 · Payment Aug 12, 2022
Funds reporting this stock among their holdings, ordered by reported position size.
Alliance Bernstein - AB Emerging Markets Opportunities ETFEMOP46.28M2.16%2.15B USD0.70%$51.04+0.10%
Vanguard FTSE Emerging Markets ETFVWO22.73M0.01%168.5B USD0.06%$59.76+1.12%
Avantis Emerging Markets Equity ETFAVEM20.43M0.07%28.17B USD0.33%$94.11+0.93%
State Street SPDR Portfolio Emerging Markets ETFSPEM18.07M0.10%17.75B USD0.07%$52.21+1.32%
Vanguard Total International Stock ETFVXUS10.6M0.00%665.7B USD0.05%$84.82+0.86%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM4.67M0.05%9.61B USD0.39%$40.01+1.07%
Dimensional - Emerging Core Equity Market ETFDFAE4.43M0.04%10.05B USD0.29%$39.40+0.97%
Vanguard FTSE All-World ex-US ETFVEU4.28M0.00%98.6B USD0.04%$82.82+0.78%Alliance Bernstein - AB Emerging Markets Opportunities ETFEMOPVanguard FTSE Emerging Markets ETFVWOAvantis Emerging Markets Equity ETFAVEMState Street SPDR Portfolio Emerging Markets ETFSPEMVanguard Total International Stock ETFVXUSDimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEVanguard FTSE All-World ex-US ETFVEUAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
